CoV-50 test to determine complications after Covid-19 disease is ready to use!

Based on the excellent results of the validation of the CoV-50 test on 327 Covid-19 patients in the Crit-CoV-U study, the BfArM issued a special approval according to Section 11 (1) MPG on December 30, 2020. On January 22nd, 2021, the regular approval of the DiaPat-CoV-50 test took place. These first study results were first provided on the LANCET Pre-Print Server on February 23, 2021. Since May 3rd, 2021, the accepted paper is published in the LANCET journal EClinicalMedicine.

This means that every doctor in Germany is entitled to carry out the CoV-50 test for the early molecular detection of the Covid-19 course in order to prevent a severe course in time.

Further information can be found here.

-

Backgound and understanding of the biological age

The study published in The Lancet Healthy Longevity, aimed to identify and validate a urinary peptidomics profile (UPP) differentiating healthy from unhealthy ageing in the general population. The generated UPP predictor was tested in independent patient cohorts, and targetable molecular pathways were found that underlie age-related chronic diseases.
The UPP signature indicative of ageing reflects fibrosis and extracellular matrix remodelling and was associated with risk factors and adverse health outcomes in the population and with accelerated ageing in patients. This study may help to shift focus from the ontology of diseases to shared disease mechanisms, in particular ageing-related fibrotic degeneration.